Treat-to-target strategies for low-density lipoprotein cholesterol and triglyceride levels for primary and secondary prevention of cardiovascular disease in adults with dyslipidaemia.

Cochrane Database Syst RevSep 28, 2026 (epub)
Clinical ResearchCardiology

Kamyar Shokraee, Juan Va Franco, Petek Eylul Taneri et al.

✦ AI-curated · Sources linked

In 30 seconds

This Cochrane systematic review protocol aims to assess the effectiveness of treat-to-target strategies for managing low-density lipoprotein cholesterol and triglyceride levels in adults with dyslipidaemia. The review will compare goal-directed lipid-lowering therapy against no-target strategies in both primary and secondary prevention of cardiovascular disease.

Key findings

  • The review will evaluate benefits and harms of treat-to-target versus no-target strategies.
  • Focus is on adults with dyslipidaemia for cardiovascular disease prevention.

Why it matters

Understanding the effectiveness of treat-to-target strategies can guide clinicians in optimizing lipid management for patients at risk of cardiovascular disease, potentially improving patient outcomes.

Source

PubMed · PMID 42803656

Published in Cochrane Database Syst Rev. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.